繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 药品专题 >> 瑞加德松注射剂|Lexiscan(Regadenoson Injection)

瑞加德松注射剂|Lexiscan(Regadenoson Injection)

2014-09-28 03:40:54  作者:新特药房  来源:互联网  浏览次数:1188  文字大小:【】【】【
简介:英文药名:Lexiscan(Regadenoson)Injection 中文药名:瑞加德松注射剂 生产厂家: CV Therapeutics, Inc.药品介绍Lexiscan(regadenoson)注射剂批准日期:2008年4月10日;公司: CV Therapeutics, Inc. ...

英文药名:Lexiscan(Regadenoson Injection)

中文药名:瑞加德松预灌封注射器

生产厂家: 安斯泰来制药美国公司
药品介绍
LEXISCAN®(瑞加德松 regadenoson)注射静脉使用
最初美国批准:2008
目前的主要变化
警告和注意事项,心肌缺血 07/2014
警告和注意事项,房颤/房扑  07/2014
警告和注意事项  07/2014
警告和注意事项,脑血管意外 07/2014
适应症和用法
Lexiscan是患者无法接受适当的运动负荷指示(MPI)放射性核素心肌灌注显像药理应激剂。
用法用量
•Lexiscan的推荐剂量为5毫升(0.4毫克的regadenoson)通过快速静脉注射;紧接着生理盐水冲洗和放射性药物。
剂型和规格
•一次性使用预灌封注射器:注射液含0.4的regadenoson毫克/毫升5(0.08毫克/毫升)
禁忌症
不要给予Lexiscan给患者:
•二线或三阶度房室传导阻滞,或
•窦房结功能障碍
除非患者有一个正常起搏器。
警告和注意事项
•心肌缺血。发生致命的心脏事件。避免患者症状或急性心肌缺血征象使用,例如不稳定型心绞痛或心血管功能不稳定,谁可能会面临更大的风险。心脏复苏设备和训练有素的工作人员shoulderstand是给药前用。
•窦房(SA)和房室结块。腺苷受体激动剂,包括Lexiscan,可以抑制SA和AV节点,并可能导致一度,二度或三度房室传导阻滞或窦性心动过缓。
•房颤/房扑。新发或快速心室反应和心房扑动复发性房颤havebeen报道。
•过敏反应,包括过敏性休克。过敏反应,血管性水肿,心脏或呼吸骤停,呼吸困难,血氧饱和度下降,低血压,咽喉发紧,荨麻疹和发生皮疹。有人员和设备复苏立即可用。
•低血压。腺苷受体激动剂,包括Lexiscan,引起血管扩张,低血压。严重低血压的风险可能会在患者的植物神经功能紊乱,狭窄的心脏瓣膜病,心包炎或心包积液,狭窄的颈动脉疾病脑血管供血不足,血容量不足或更高版本。
•高血压。腺苷受体激动剂,包括Lexiscan,可诱导血压临床显著提高特别是在患者的高血压病史并且当MPI包含低水平锻炼。
•支气管收缩。腺苷受体激动剂,包括Lexiscan,可能诱发的呼吸困难,支气管收缩和呼吸妥协患者COPD或哮喘。复苏措施shoulderstand用。
•扣押。 Lexiscan可降低癫痫发作阈值。新的发作或抽搐发作复发已经发生。有些癫痫发作是长期的,迫切需要抗惊厥管理。在谁的经验扣押协办Lexiscan患者不推荐使用的甲基黄嘌呤。
•脑血管意外(中风)。出血和发生缺血性脑血管意外。
不良反应
最常见的(发病率≥5%),以Lexiscan不良反应有呼吸困难,头痛,潮红,胸部不适,头晕,心绞痛,胸痛和恶心。
药物相互作用
•甲基黄嘌呤,E. G.,咖啡因,氨茶碱和茶碱,干扰Lexiscan的活性。
•氨茶碱可以用来衰减严重和​​/或持续的不良反应Lexiscan。
•双嘧达莫可以增加Lexiscan的活性。如果可能的话,扣双嘧达莫为Lexiscan给药前至少两天。
处方修改日期:7/2014
注:本品管制药品,仅供研究使用


FULL PRESCRIBING INFORMATION: CONTENTS*
LEXISCAN(REGADENOSON)SOLUTION;INTRAVENOUS
1 INDICATIONS AND USAGE

Lexiscan® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.
2 DOSAGE AND ADMINISTRATION
The recommended intravenous dose of Lexiscan is 5 mL (0.4 mg regadenoson)
• Administer Lexiscan as a rapid (approximately 10 seconds) injection into a peripheral vein using a 22 gauge or larger catheter or needle.
• Administer a 5 mL saline flush immediately after the injection of Lexiscan.
• Administer the radionuclide myocardial perfusion imaging agent 10–20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as Lexiscan.
NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Lexiscan if it contains particulate matter or is discolored.
3 DOSAGE FORMS AND STRENGTHS
• Single-use pre-filled syringe: Injection solution containing regadenoson 0.4 mg/5 mL (0.08 mg/mL).
4 CONTRAINDICATIONS
Do not administer Lexiscan to patients with:
• Second- or third- degree AV block, or
• sinus node dysfunction
unless these patients have a functioning artificial pacemaker [see Warnings and Precautions (5.2)].
5 WARNINGS AND PRECAUTIONS
5.1 Myocardial Ischemia
Fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest have occurred following Lexiscan injection. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to Lexiscan. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan. If serious reactions to Lexiscan occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by Lexiscan [see Overdosage (10)].
5.2 Sinoatrial and Atrioventricular Nodal Block
Adenosine receptor agonists, including Lexiscan, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention. In clinical trials first-degree AV block (PR prolongation > 220 msec) developed in 3% of patients within 2 hours of Lexiscan administration; transient second-degree AV block with one dropped beat was observed in one patient receiving Lexiscan. In post-marketing experience, third-degree heart block and asystole within minutes of Lexiscan administration have occurred [see Adverse Reactions (6.2)].
5.3 Atrial Fibrillation/Atrial Flutter
New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported following Lexiscan injection [see Adverse Reactions (6.2)].
5.4 Hypersensitivity, Including Anaphylaxis
Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria and rashes have occurred. In clinical trials, hypersensitivity reactions were reported in fewer than 1 percent of patients [see Adverse Reactions (6.1)]. Have personnel and resuscitative equipment immediately available.
5.5 Hypotension
Adenosine receptor agonists, including Lexiscan, induce arterial vasodilation and hypotension. In clinical trials, decreased systolic blood pressure (> 35 mm Hg) was observed in 7% of patients and decreased diastolic blood pressure (> 25 mm Hg) was observed in 4% of patients within 45 min of Lexiscan administration. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency. In post-marketing experience, syncope, transient ischemic attacks and seizures have been observed [see Adverse Reactions (6.2)].
5.6 Hypertension
Administration of adenosine receptor agonists, including Lexiscan, may result in clinically significant increases in blood pressure in some patients. Among patients who experienced an increase in blood pressure in clinical trials, the increase was observed within minutes of Lexiscan administration. Most increases resolved within 10 to 15 minutes, but in some cases, increases were observed at 45 minutes following administration [see Clinical Pharmacology (12.2)]. In post-marketing experience, cases of potentially clinically significant hypertension have been reported, particularly with underlying hypertension and when low-level exercise was included in the MPI [see Adverse Reactions (6.2)].
5.7 Bronchoconstriction
Adenosine receptor agonists, including Lexiscan, may cause dyspnea, bronchoconstriction, and respiratory compromise. Appropriate bronchodilator therapy and resuscitative measures should be available prior to Lexiscan administration [see Adverse Reactions (6.1), Clinical Pharmacology (12.2), Overdosage (10) and Patient Counseling Information (17)].
5.8 Seizure
Lexiscan may lower the seizure threshold. New-onset or recurrence of convulsive seizures has occurred following Lexiscan injection. Some seizures are prolonged and require emergent anticonvulsive management. Aminophylline may increase the risk of seizures associated with Lexiscan injection. Methylxanthine use is not recommended in patients who experience a seizure in association with Lexiscan administration.
5.9 Cerebrovascular Accident (Stroke)
Hemorrhagic and ischemic cerebrovascular accidents have occurred. Hemodynamic effects of Lexiscan including hypotension or hypertension may be associated with these adverse reactions [see Warnings and Precautions (5.5) and (5.6)].
6 ADVERSE REACTIONS
The following adverse reactions are discussed in more detail in other sections of the labeling.
• Myocardial Ischemia [ see Warnings and Precautions (5.1)]
• Sinoatrial and Atrioventricular Nodal Block [ see Warnings and Precautions (5.2)]
• Atrial Fibrillation/Atrial Flutter [ see Warnings and Precautions (5.3)]
• Hypersensitivity, Including Anaphylaxis [ see Warnings and Precautions (5.4)]
• Hypotension [ see Warnings and Precautions (5.5)]
• Hypertension [ see Warnings and Precautions (5.6)]
• Bronchoconstriction [ see Warnings and Precautions (5.7)]
• Seizure [ see Warnings and Precautions (5.8)]
• Cerebrovascular Accident (Stroke) [ see Warnings and Precautions (5.9)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
During clinical development, 1,651 subjects were exposed to Lexiscan, with most receiving 0.4 mg as a rapid (≤ 10 seconds) intravenous injection. Most of these subjects received Lexiscan in two clinical studies that enrolled patients who had no history of bronchospastic lung disease as well as no history of a cardiac conduction block of greater than first-degree AV block, except for patients with functioning artificial pacemakers. In these studies (Studies 1 and 2), 2,015 patients underwent myocardial perfusion imaging after administration of Lexiscan (N = 1,337) or Adenoscan® (N = 678). The population was 26–93 years of age (median 66 years), 70% male and primarily Caucasian (76% Caucasian, 7% African American, 9% Hispanic, 5% Asian). Table 1 shows the most frequently reported adverse reactions.
Overall, any adverse reaction occurred at similar rates between the study groups (80% for the Lexiscan group and 83% for the Adenoscan group). Aminophylline was used to treat the reactions in 3% of patients in the Lexiscan group and 2% of patients in the Adenoscan group. Most adverse reactions began soon after dosing, and generally resolved within approximately 15 minutes, except for headache which resolved in most patients within 30 minutes.
Table 1 Adverse Reactions in Studies 1 and 2 Pooled (Frequency ≥ 5%)

Lexiscan
N = 1,337

Adenoscan
N = 678

Dyspnea

28%

26%

Headache

26%

17%

Flushing

16%

25%

Chest Discomfort

13%

18%

Angina Pectoris or ST Segment Depression

12%

18%

Dizziness

8%

7%

Chest Pain

7%

10%

Nausea

6%

6%

Abdominal Discomfort

5%

2%

Dysgeusia

5%

7%

Feeling Hot

5%

8%

ECG Abnormalities
The frequency of rhythm or conduction abnormalities following Lexiscan or Adenoscan is shown in Table 2 [see Warnings and Precautions (5.2)].
Table 2 Rhythm or Conduction Abnormalities* in Studies 1 and 2

Lexiscan
N / N evaluable (%)

Adenoscan
N / N evaluable (%)

Rhythm or conduction abnormalities†

332/1275 (26%)

192/645 (30%)

Rhythm abnormalities

260/1275 (20%)

131/645 (20%)

PACs

86/1274 (7%)

57/645 (9%)

PVCs

179/1274 (14%)

79/645 (12%)

First-degree AV block (PR prolongation > 220 msec)

34/1209 (3%)

43/618 (7%)

Second-degree AV block

1/1209 (0.1%)

9/618 (1%)

AV conduction abnormalities (other than AV blocks)

1/1209 (0.1%)

0/618 (0%)

Ventricular conduction abnormalities

64/1152 (6%)

31/581 (5%)

12-lead ECGs were recorded before and for up to 2 hrs after dosing
includes rhythm abnormalities (PACs, PVCs, atrial fibrillation/flutter, wandering atrial pacemaker, supraventricular or ventricular arrhythmia) or conduction abnormalities, including AV block
Respiratory Abnormalities
In a randomized, placebo-controlled trial (Study 3) of 999 subjects with asthma (n=532) or stable chronic obstructive pulmonary disease (n=467), the overall incidence of pre-specified respiratory adverse reactions was greater in the Lexiscan group compared to the placebo group (p < 0.001). Most respiratory adverse reactions resolved without therapy; a few subjects received aminophylline or a short acting bronchodilator. No differences were observed between treatment arms in the reduction of >15% from baseline at two-hours in FEV1 (Table 3).
Table 3 Respiratory Adverse Effects in Study 3*

Asthma Cohort COPD Cohort

Lexiscan

(N=356)

Placebo

(N=176)

Lexiscan

(N=316)

Placebo

(N=151)

Overall Pre-specified Respiratory Adverse Reaction

12.9%

2.3%

19.0%

4.0%

    Dyspnea

10.7%

1.1%

18.0%

2.6%

    Wheezing

3.1%

1.1%

0.9%

0.7%

FEV1 reduction >15%

1.1%

2.9%

4.2%

5.4%

All subjects continued the use of their respiratory medications as prescribed prior to administration of Lexiscan.
Patients may have reported more than one type of adverse reaction. Adverse reactions were collected up to 24 hours following drug administration. Pre-specified respiratory adverse reactions included dyspnea, wheezing, obstructive airway disorder, dyspnea exertional, and tachypnea.
Change from baseline at 2 hours
Renal Impairment
In a randomized, placebo-controlled trial of 504 subjects (Lexiscan n=334 and placebo n=170) with a diagnosis or risk factors for coronary artery disease and NKFK/DOQI Stage III or IV renal impairment (defined as GFR 15-59 mL/min/1.73 m2), no serious adverse events were reported through the 24-hour follow-up period.
6.2 Post-Marketing Experience
Cardiovascular
Myocardial infarction, cardiac arrest, ventricular arrhythmias, supraventricular tachyarrhythmias including atrial fibrillation with rapid ventricular response (new-onset or recurrent), atrial flutter, heart block (including third-degree block), asystole, marked hypertension, symptomatic hypotension in association with transient ischemic attack, seizures and syncope [see Warnings and Precautions (5.1), (5.2), (5.3), (5.5), (5.6) and (5.8)] have been reported. Some events required intervention with fluids and/or aminophylline [see Overdosage (10)]. QTc prolongation shortly after Lexiscan administration has been reported.
Central Nervous System
Tremor, seizure, transient ischemic attack, and cerebrovascular accident including intracranial hemorrhage [see Warnings and Precautions (5.8) and (5.9)].
Gastrointestinal
Abdominal pain, occasionally severe, has been reported a few minutes after Lexiscan administration, in association with nausea, vomiting, or myalgias; administration of aminophylline, an adenosine antagonist, appeared to lessen the pain. Diarrhea and fecal incontinence have also been reported following Lexiscan administration.
Hypersensitivity
Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, rashes have occurred and have required treatment including resuscitation [see Warnings and Precautions (5.4)].
Musculoskeletal
Musculoskeletal pain has occurred, typically 10-20 minutes after Lexiscan administration; the pain was occasionally severe, localized in the arms and lower back and extended to the buttocks and lower legs bilaterally. Administration of aminophylline appeared to lessen the pain.
Respiratory
Respiratory arrest, dyspnea and wheezing have been reported following Lexiscan administration.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Lexiscan exposure. 
7 DRUG INTERACTIONS
No formal pharmacokinetic drug interaction studies have been conducted with Lexiscan.
7.1 Effects of Other Drugs on Lexiscan
• Methylxanthines (e.g., caffeine, aminophylline and theophylline) are non-specific adenosine receptor antagonists that interfere with the vasodilation activity of Lexiscan [ see Clinical Pharmacology (12.2) and Patient Counseling Information (17)]. Patients should avoid consumption of any products containing methylxanthines as well as any drugs containing theophylline or aminophylline for at least 12 hours before Lexiscan administration. Aminophylline may be used to attenuate severe or persistent adverse reactions to Lexiscan [ see Overdosage (10)].
• In clinical studies, Lexiscan was administered to patients taking other cardioactive drugs (i.e., β-blockers, calcium channel blockers, ACE inhibitors, nitrates, cardiac glycosides, and angiotensin receptor blockers) without reported adverse reactions or apparent effects on efficacy.
• Dipyridamole may change the effects of Lexiscan. When possible, withhold dipyridamole for at least two days prior to Lexiscan administration.
7.2 Effect of Lexiscan on Other Drugs
Regadenoson does not inhibit the metabolism of substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 in human liver microsomes, indicating that it is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 enzymes.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category C:
There are no adequate well-controlled studies with Lexiscan in pregnant women. Lexiscan should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus.
Reproductive studies in rats showed that regadenoson doses 10 and 20 times the maximum recommended human dose (MRHD) based on body surface area, caused reduced fetal body weights and significant ossification delays in fore- and hind limb phalanges and metatarsals; however, maternal toxicity also occurred at these doses. Skeletal variations were increased in all treated groups. In rabbits, there were no teratogenic effects in offspring at regadenoson doses 4 times the MRHD, although signs of maternal toxicity occurred at this dose. At regadenoson doses equivalent to 12 and 20 times the MRHD, maternal toxicity occurred along with increased embryo-fetal loss and fetal malformations. It is not clear whether malformations that occurred at maternally toxic doses of regadenoson in both animal species were due to fetal drug effects or only to the maternal toxic effects.
Because animals received repeated doses of regadenoson, their exposure was significantly higher than that achieved with the standard single dose administered to humans [see Nonclinical Toxicology (13.2)].
8.3 Nursing Mothers
It is not known whether Lexiscan is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from Lexiscan in nursing infants, the decision to interrupt nursing after administration of Lexiscan or not to administer Lexiscan, should take into account the importance of the drug to the mother. Based on the pharmacokinetics of Lexiscan, it should be cleared 10 hours after administration. Therefore, nursing women may consider interrupting nursing for 10 hours after administration.
8.4 Pediatric Use
Safety and effectiveness in pediatric patients (< 18 years of age) have not been established.
8.5 Geriatric Use
Of the 1,337 patients receiving Lexiscan in Studies 1 and 2, 56% were 65 years of age and over and 24% were 75 years of age and over. Older patients (> 75 years of age) had a similar adverse event profile compared to younger patients (< 65 years of age), but had a higher incidence of hypotension (2% vs. ≤ 1%).
8.6 Renal Impairment
Lexiscan was assessed in a randomized, placebo-controlled trial of patients with NKFK/DOQI Stage III or IV renal impairment (defined as a GFR 15-59 mL/min/1.73 m2). No serious adverse events were reported through the 24-hour follow-up period [see Adverse Reactions (6.1)].
10 OVERDOSAGE
Lexiscan overdosage may result in serious reactions [see Warnings and Precautions (5)]. In a study of healthy volunteers, symptoms of flushing, dizziness and increased heart rate were assessed as intolerable at Lexiscan doses greater than 0.02 mg/kg.
Aminophylline to Reverse Effects
Methylxanthines, such as caffeine, aminophylline, and theophylline, are competitive adenosine receptor antagonists and aminophylline has been used to terminate persistent pharmacodynamic effects. Aminophylline may be administered in doses ranging from 50 mg to 250 mg by slow intravenous injection (50 mg to 100 mg over 30–60 seconds). Methylxanthine use is not recommended in patients who experience a seizure in association with Lexiscan administration.
11 DESCRIPTION
Regadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator [see Clinical Pharmacology (12.1)]. Regadenoson is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its structural formula is:


The molecular formula for regadenoson is C15H18N8O5 • H2O and its molecular weight is 408.37.
Lexiscan is a sterile, nonpyrogenic solution for intravenous injection. The solution is clear and colorless. Each 1 mL in the 5 mL pre-filled syringe contains 0.084 mg of regadenoson monohydrate, corresponding to 0.08 mg regadenoson on an anhydrous basis, 10.9 mg dibasic sodium phosphate dihydrate or 8.7 mg dibasic sodium phosphate anhydrous, 5.4 mg monobasic sodium phosphate monohydrate, 150 mg propylene glycol, 1 mg edetate disodium dihydrate, and Water for Injection, with pH between 6.3 and 7.7.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Regadenoson is a low affinity agonist (Ki ≈ 1.3 µM) for the A2A adenosine receptor, with at least 10-fold lower affinity for the A1 adenosine receptor (Ki > 16.5 µM), and weak, if any, affinity for the A2B and A3 adenosine receptors. Activation of the A2A adenosine receptor by regadenoson produces coronary vasodilation and increases coronary blood flow (CBF).
12.2 Pharmacodynamics
Coronary Blood Flow
Lexiscan causes a rapid increase in CBF which is sustained for a short duration. In patients undergoing coronary catheterization, pulsed-wave Doppler ultrasonography was used to measure the average peak velocity (APV) of coronary blood flow before and up to 30 minutes after administration of regadenoson (0.4 mg, intravenously). Mean APV increased to greater than twice baseline by 30 seconds and decreased to less than twice the baseline level within 10 minutes [see Clinical Pharmacology (12.3)].
Myocardial uptake of the radiopharmaceutical is proportional to CBF. Because Lexiscan increases blood flow in normal coronary arteries with little or no increase in stenotic arteries, Lexiscan causes relatively less uptake of the radiopharmaceutical in vascular territories supplied by stenotic arteries. MPI intensity after Lexiscan administration is therefore greater in areas perfused by normal relative to stenosed arteries.
Effect of Aminophylline
Aminophylline (100 mg, administered by slow iv injection over 60 seconds) injected 1 minute after 0.4 mg Lexiscan in subjects undergoing cardiac catheterization, was shown to shorten the duration of the coronary blood flow response to Lexiscan as measured by pulsed-wave Doppler ultrasonography [see Overdosage (10)].
Effect of Caffeine
Ingestion of caffeine decreases the ability to detect reversible ischemic defects. In a placebo-controlled, parallel group clinical study, patients with known or suspected myocardial ischemia received a baseline rest/stress MPI followed by a second stress MPI. Patients received caffeine or placebo 90 minutes before the second Lexiscan stress MPI. Following caffeine administration (200 or 400 mg), the mean number of reversible defects identified was reduced by approximately 60%. This decrease was statistically significant [see Drug Interactions (7.1) and Patient Counseling Information (17)].
Hemodynamic Effects
In clinical studies, the majority of patients had an increase in heart rate and a decrease in blood pressure within 45 minutes after administration of Lexiscan. Maximum hemodynamic changes after Lexiscan and Adenoscan in Studies 1 and 2 are summarized in Table 4.
Table 4 Hemodynamic Effects in Studies 1 and 2

Vital Sign Parameter Lexiscan
N = 1,337
Adenoscan
N = 678

Heart Rate

> 100 bpm

22%

13%

Increase > 40 bpm

5%

3%

Systolic Blood Pressure

< 90 mm Hg

2%

3%

Decrease > 35 mm Hg

7%

8%

≥ 200 mm Hg

1.9%

1.9%

Increase ≥ 50 mm Hg

0.7%

0.8%

≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline

4.6%

3.2%

Diastolic Blood Pressure

< 50 mm Hg

2%

4%

Decrease > 25 mm Hg

4%

5%

≥ 115 mm Hg

0.9%

0.9%

Increase ≥ 30 mm Hg

0.5%

1.1%

Respiratory Effects
The A2B and A3 adenosine receptors have been implicated in the pathophysiology of bronchoconstriction in susceptible individuals (i.e., asthmatics). In in vitro studies, regadenoson has not been shown to have appreciable binding affinity for the A2B and A3 adenosine receptors.
In a randomized, placebo-controlled clinical trial (Study 3) of 999 subjects with a diagnosis, or risk factors for, coronary artery disease and concurrent asthma or COPD, the incidence of respiratory adverse reactions (dyspnea, wheezing) was greater with Lexiscan compared to placebo. Moderate (2.5%) or severe (<1%) respiratory reactions were observed more frequently in the Lexiscan group compared to placebo [see Adverse Reactions (6.1)].
12.3 Pharmacokinetics
In healthy volunteers, the regadenoson plasma concentration-time profile is multi-exponential in nature and best characterized by 3-compartment model. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection of Lexiscan and parallels the onset of the pharmacodynamic response. The half-life of this initial phase is approximately 2 to 4 minutes. An intermediate phase follows, with a half-life on average of 30 minutes coinciding with loss of the pharmacodynamic effect. The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [see Clinical Pharmacology (12.2)]. Within the dose range of 0.3–20 µg/kg in healthy subjects, clearance, terminal half-life or volume of distribution do not appear dependent upon the dose.
A population pharmacokinetic analysis including data from subjects and patients demonstrated that regadenoson clearance decreases in parallel with a reduction in creatinine clearance and clearance increases with increased body weight. Age, gender, and race have minimal effects on the pharmacokinetics of regadenoson.
Special Populations
Renally Impaired Patients: The disposition of regadenoson was studied in 18 subjects with various degrees of renal function and in 6 healthy subjects. With increasing renal impairment, from mild (CLcr 50 to < 80 mL/min) to moderate (CLcr 30 to < 50 mL/min) to severe renal impairment (CLcr < 30 mL/min), the fraction of regadenoson excreted unchanged in urine and the renal clearance decreased, resulting in increased elimination half-lives and AUC values compared to healthy subjects (CLcr ≥ 80 mL/min). However, the maximum observed plasma concentrations as well as volumes of distribution estimates were similar across the groups. The plasma concentration-time profiles were not significantly altered in the early stages after dosing when most pharmacologic effects are observed. No dose adjustment is needed in patients with renal impairment.
Patients with End Stage Renal Disease: The pharmacokinetics of regadenoson in patients on dialysis has not been assessed.
Hepatically Impaired Patients: The influence of hepatic impairment on the pharmacokinetics of regadenoson has not been evaluated. Because greater than 55% of the dose is excreted in the urine as unchanged drug and factors that decrease clearance do not affect the plasma concentration in the early stages after dosing when clinically meaningful pharmacologic effects are observed, no dose adjustment is needed in patients with hepatic impairment.
Geriatric Patients: Based on a population pharmacokinetic analysis, age has a minor influence on the pharmacokinetics of regadenoson. No dose adjustment is needed in elderly patients.
Metabolism
The metabolism of regadenoson is unknown in humans. Incubation with rat, dog, and human liver microsomes as well as human hepatocytes produced no detectable metabolites of regadenoson.
Excretion
In healthy volunteers, 57% of the regadenoson dose is excreted unchanged in the urine (range 19–77%), with an average plasma renal clearance around 450 mL/min, i.e., in excess of the glomerular filtration rate. This indicates that renal tubular secretion plays a role in regadenoson elimination.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Regadenoson was negative in the Ames bacterial mutation assay, chromosomal aberration assay in Chinese hamster ovary (CHO) cells, and mouse bone marrow micronucleus assay.
Long-term animal studies have not been conducted to evaluate Lexiscan's carcinogenic potential or potential effects on fertility.
13.2 Animal Toxicology and/or Pharmacology
Reproductive Toxicology Studies
Reproduction studies were conducted in rabbits and rats using doses of Lexiscan that were 2 to 20 times (rats) and 4 to 20 times (rabbits) the maximum recommended human dose (MRHD), based on body surface area comparison.
When administered to rabbits during organogenesis, regadenoson caused maternal toxicity including tachypnea, soft, liquid or scant feces, and localized alopecia in all treated groups, and caused reduction in body weight and feed consumption at 0.3 and 0.5 mg/kg/day (12 and 20 X MRHD, respectively). At regadenoson doses equivalent to 12 and 20 times the MRHD, maternal toxicity occurred along with decreased number of live fetuses, reduced fetal body weight, and occurrence of fetal variations and malformations. At regadenoson doses equivalent to 20 times the MRHD, resorptions were increased and fetal body weights reduced. Fetal malformations included microphthalmia (1/116 at 20 X MRHD), interrelated vertebrae/rib alterations (2/145 and 2/116 each at 12 and 20 X MRHD), and misaligned caudal vertebrae (3/145 at 12 X MRHD). Fetal toxicity was only observed at maternally toxic doses. The no effect dose level for fetal toxicity is 0.1 mg/kg (4 X MRHD). A no effect dose level was not identified for maternal toxicity.
When regadenoson was administered to pregnant rats during the period of major organogenesis, 4/25 rats from the 1.0 mg/kg/day group (20 X MRHD) and 1/25 rats from the 0.8 mg/kg (16 X MRHD) group died immediately following the first dose of regadenoson. All dams had decreased motor activity and one was gasping post-dosing. At doses ≥ 0.5 mg/kg (10 X MRHD), maternal toxicity included decreased motor activity, increased limb extension, excess salivation, and reduction in body weight and feed consumption. At doses ≥ 0.5 mg/kg, fetal body weights were significantly reduced and significant ossification delays were observed in fore- and hind limb phalanges and metatarsals. Skeletal malformations included delayed ossification of the skull (1/167), and hemivertebra present at a thoracic vertebra (1/167), observed at 16-20 X MRHD, and small arches of a lumbar and sacral vertebrae (1/174) observed at 2 X MRHD. The no effect dose level for maternal toxicity is 0.1 mg/kg/day (2 X MRHD).
Cardiomyopathy
Minimal cardiomyopathy (myocyte necrosis and inflammation) was observed in rats following single dose administration of regadenoson. Increased incidence of minimal cardiomyopathy was observed on day 2 in males at doses of 0.08, 0.2 and 0.8 mg/kg (1/5, 2/5, and 5/5) and in females (2/5) at 0.8 mg/kg. In a separate study in male rats, the mean arterial pressure was decreased by 30 to 50% of baseline values for up to 90 minutes at regadenoson doses of 0.2 and 0.8 mg/kg, respectively. No cardiomyopathy was noted in rats sacrificed 15 days following single administration of regadenoson. The mechanism of the cardiomyopathy induced by regadenoson was not elucidated in this study but was associated with the hypotensive effects of regadenoson. Profound hypotension induced by vasoactive drugs is known to cause cardiomyopathy in rats.
Local Irritation
Intravenous administration of Lexiscan to rabbits resulted in perivascular hemorrhage, vein vasculitis, inflammation, thrombosis and necrosis, with inflammation and thrombosis persisting through day 8 (last observation day). Perivascular administration of Lexiscan to rabbits resulted in hemorrhage, inflammation, pustule formation and epidermal hyperplasia, which persisted through day 8 except for the hemorrhage which resolved. Subcutaneous administration of Lexiscan to rabbits resulted in hemorrhage, acute inflammation, and necrosis; on day 8 muscle fiber regeneration was observed.
14 CLINICAL STUDIES
The efficacy and safety of Lexiscan were determined relative to Adenoscan in two randomized, double-blind studies (Studies 1 and 2) in 2,015 patients with known or suspected coronary artery disease who were indicated for pharmacologic stress MPI. A total of 1,871 of these patients had images considered valid for the primary efficacy evaluation, including 1,294 (69%) men and 577 (31%) women with a median age of 66 years (range 26–93 years of age). Each patient received an initial stress scan using Adenoscan (6-minute infusion using a dose of 0.14 mg/kg/min, without exercise) with a radionuclide gated SPECT imaging protocol. After the initial scan, patients were randomized to either Lexiscan or Adenoscan, and received a second stress scan with the same radionuclide imaging protocol as that used for the initial scan. The median time between scans was 7 days (range of 1–104 days).
The most common cardiovascular histories included hypertension (81%), CABG, PTCA or stenting (51%), angina (63%), and history of myocardial infarction (41%) or arrhythmia (33%); other medical history included diabetes (32%) and COPD (5%). Patients with a recent history of serious uncontrolled ventricular arrhythmia, myocardial infarction, or unstable angina, a history of greater than first-degree AV block, or with symptomatic bradycardia, sick sinus syndrome, or a heart transplant were excluded. A number of patients took cardioactive medications on the day of the scan, including β-blockers (18%), calcium channel blockers (9%), and nitrates (6%). In the pooled study population, 68% of patients had 0–1 segments showing reversible defects on the initial scan, 24% had 2–4 segments, and 9% had ≥ 5 segments.
Image Agreement
Comparison of the images obtained with Lexiscan to those obtained with Adenoscan was performed as follows. Using the 17-segment model, the number of segments showing a reversible perfusion defect was calculated for the initial Adenoscan study and for the randomized study obtained using Lexiscan or Adenoscan. The agreement rate for the image obtained with Lexiscan or Adenoscan relative to the initial Adenoscan image was calculated by determining how frequently the patients assigned to each initial Adenoscan category (0–1, 2–4, 5–17 reversible segments) were placed in the same category with the randomized scan. The agreement rates for Lexiscan and Adenoscan were calculated as the average of the agreement rates across the three categories determined by the initial scan. Studies 1 and 2 each demonstrated that Lexiscan is similar to Adenoscan in assessing the extent of reversible perfusion abnormalities (Table 5).
Table 5 Agreement Rates in Studies 1 and 2 

Study 1 Study 2

Adenoscan – Adenoscan Agreement Rate (± SE)

61 ± 3%

64 ± 4%

Adenoscan – Lexiscan Agreement Rate (± SE)

62 ± 2%

63 ± 3%

Rate Difference (Lexiscan – Adenoscan) (± SE)

95% Confidence Interval

1 ± 4%

-7.5, 9.2%

-1 ± 5%

-11.2, 8.7%

16 HOW SUPPLIED/STORAGE AND HANDLING
Lexiscan is supplied as a sterile, preservative-free solution containing 0.08 mg/mL regadenoson in the following package:
• Single-use 5 mL pre-filled plastic Ansyr ® syringes with luer-lock fitting (NDC 0469-6501-89).
Store at controlled room temperature, 25°C (77°F); excursions permitted to 15° to 30°C (59°–86°F).
17 PATIENT COUNSELING INFORMATION
Advise patients that they may be at increased risk of fatal and nonfatal heart attacks, abnormal heart rhythms, cardiac arrest, significant increase or decrease in blood pressure, hypersensitivity reactions, seizures, bronchoconstriction, or cerebrovascular accidents (stroke) with the use of Lexiscan [see Warnings and Precautions (5.1), (5.3), (5.4), (5.5), (5.6), (5.8) and (5.9)].
Patients should be instructed to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, aminophylline and theophylline for at least 12 hours before a scheduled radionuclide MPI. Question patients about a history of seizures.
Prior to Lexiscan administration, patients should be informed of the most common reactions (such as shortness of breath, headache and flushing) that have been reported in association with Lexiscan during MPI.
Patients with COPD or asthma should be informed to discuss their respiratory history and administration of pre-and post-study bronchodilator therapy with their clinician before scheduling an MPI study with Lexiscan.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=057289f4-2e18-4c1e-bed4-6c1858e2ef16
心血管造影剂瑞加德松(Lexiscan)被列入FDA观察名单
美国食品药品管理局(FDA)已将瑞加德松(Lexiscan, 阿斯特拉斯制药美国) 列入其最新的监控产品季度名单,该药物是一种心血管造影剂,有潜在的心肌梗死 (MI) 和死亡风险迹象,FDA 于上个月这样宣布说。
瑞加德松(Regadenoson)是一种选择性腺苷受体激动剂,可使冠状动脉产生舒张。这款药物用于不能接受运动压力测试患者的放射性核素心肌灌注显像。临床医师也超适用症将其用于CT影像。
FDA通过其不良事件报告系统 (FAERS) 数据库收到报告称在2013年第二季度期间,瑞加德松可能与心肌梗死和死亡有关联。自从这款药物于2008年获得FDA批准,其标签内容中已加入了心肌梗死风险警告。
FDA提醒,不能仅因为FDA将一款药物加入其观察名单就认为FDA已经断定这款药物能造成所报道的健康风险。当然,FDA将调查这之间是否确实存在因果关系。如果答案属实,FDA将考虑作出回应,如收集更多数据以更好地描述风险,修订药物的标签,或要求一个风险评估和减灾战略。
FDA一直强调,将一款药物列入观察名单不表明临床医师应该停止使用这款药物,或患者应该停止使用这款药物。瑞加德松在2011年时,因其可能的QT间期延长信号也曾被列入观察名单。这款药物的标签内容中一直有警告提示其存在危及生命的室性心律失常风险。
---------------------------------------------
产地国家: 美国
原产地英文商品名:
LEXISCAN injection 0.4mg/5ml(0.08mg/mL)/syringes 1vial
原产地英文药品名:
REGADENOSON
中文参考商品译名:
LEXISCAN 0.4毫克/5毫升(0.08毫克/毫升)/注射器 1瓶
中文参考药品译名:
瑞加德松
生产厂家中文参考译名:
安斯泰来制药美国公司
生产厂家英文名:
Astellas

责任编辑:admin


相关文章
Lexiscan (regadenoson)注射剂
 

最新文章

更多

· BOTOX Vista Injection(...
· D-SORBITOL Oral Sol(D...
· Lymphoseek(锝替马诺噻...
· L-CARN(左旋肉碱溶脂针)
· 注射用醋酸兰瑞肽|Somat...
· Signifor LAR(帕瑞肽长...
· 肢端肥大症长效药物Sign...
· Kybella(deoxycholic ac...
· SAXENDA(liraglutide [r...
· Saxenda(Liraglutide)获...

推荐文章

更多

· BOTOX Vista Injection(...
· D-SORBITOL Oral Sol(D...
· Lymphoseek(锝替马诺噻...
· L-CARN(左旋肉碱溶脂针)
· 注射用醋酸兰瑞肽|Somat...
· Signifor LAR(帕瑞肽长...
· 肢端肥大症长效药物Sign...
· Kybella(deoxycholic ac...
· SAXENDA(liraglutide [r...
· Saxenda(Liraglutide)获...

热点文章

更多